A Phase 1 study, first in human, of ARV-393 in adult participants with advanced-stage non-Hodgkin lymphoma.
Contact Information for Access
Phase
FASE I (FIH)
Status
IN ATTIVAZIONE
Objective of the study
The purpose of this FIH study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ARV-393 as monotherapy and in combination with glofitamab in adult participants with advanced-stage non-Hodgkin lymphoma (NHL).
ClinicalTrials.gov ID: NCT06393738
Sponsor: Arvinas Inc.
Pathologies
Onco-hematological (hematological cancers/malignancies)
Medication
ARV-393 (BCL6 transcriptional factor inhibitor)
Glofitamab
Obinutuzumab
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with non-Hodgkin lymphoma (NHL).
View the full study Back to search page